About ExonBio
ExonBio is a Healthcare company based in San Diego (United States) founded in 1996. It operates as an antibody and protein development services are offered. ExonBio offers products and services including SARS-CoV-2 Antibody, Influenza A Antibody, Influenza B Antibody, Ebola Antibody, and SPIN Platform. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Cell and Molecular Biology. Its competitors include Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
ExonBio provides services in recombinant antibody development (rabbit, chicken, and Llama), antibody engineering, protein production using mammalian expression ( transient expression, mammalian expression systems, and stable cell pool) and bacterial expression system, molecular biology services (gene synthesis, gene cloning, site-directed mutagenesis). Additionally, the company manufactures some reagents for research such as enzymes, competent cells, and growth factors.
- Headquarters San Diego, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website exonbio.com
- Social LinkedIn Facebook
- Latest Funding Round$162.67K (USD), Grant
Jun 2010
- Investors
Products & Services of ExonBio
ExonBio offers a comprehensive portfolio of products and services, including SARS-CoV-2 Antibody, Influenza A Antibody, Influenza B Antibody, Ebola Antibody, and SPIN Platform.
Antibody for detecting SARS-CoV-2 virus in medical diagnostics
Antibody for identifying Influenza A in testing applications
Antibody for detecting Influenza B in diagnostic assays
Antibody for Ebola virus detection in healthcare settings
Platform for high-throughput screening of antibody repertoires
Funding Insights of ExonBio
- Total Rounds 2
- Last Round Grant — $162,668
- First Round $162,668
(May 2010)
- Investors Count 1
All 2 funding rounds of ExonBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in ExonBio
ExonBio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for ExonBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ExonBio
3 people are tracked at ExonBio (1 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Kunhua Chen | CEO | Leadership |
Krisha Doshi | Product Manager | Team |
Aras Arya | Yönetici Asistanı | Team |
Complete people profiles for ExonBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ExonBio
3 dated milestones of ExonBio across 14 years, from founding to its latest funding, stage changes and deals.
- Founded ExonBio is founded.
- Funding First funding round of $163K.
- Funding Latest funding round, Grant, of $163K.
Competitors of ExonBio
ExonBio has 10 listed competitors in our database, 10 of them funded. They include Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. | |
| biognosys.com | 2008 | Schlieren, Switzerland | $9.13M | – | Proteomics services are delivered via discovery and targeted platforms. | |
| elektrofi.com | 2016 | Boston, United States | $152.25M | 71 | Digital platform transforming the delivery of biologic medicines | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis | |
| arzeda.com | 2008 | Seattle, United States | $94.96M | 66 | Synthetic enzymes are designed using computational technology for industrial applications. | |
| aalphabio.com | 2017 | Seattle, United States | $45.24M | 48 | Developer of cell-based tool for the measurements of protein interactions | |
| glyphic.bio | 2021 | San Francisco, United States | $39.2M | 26 | Next-generation protein sequencing platform is developed for proteome analysis. | |
| dynamic-biosensors.com | 2011 | Planegg, Germany | $5.83M | 51 | Label-free solutions for molecular interactions and biophysical analysis are provided. |
Detailed competitors of ExonBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ExonBio
The website of ExonBio (exonbio.com) receives about 4K visits a month.
- Monthly visits4K
▲ 291% vs previous month
Websites whose visitors overlap most with ExonBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| eurogentec.com | 100% | 40.4K | #771,641 | View details | |
| biosyn.com | 95% | 41K | #862,186 | View details | |
molecularthroughput.com | molecularthroughput.com | 90% | – | – | – |
| genewiz.com | 85% | 218.6K | #157,582 | View details | |
bio-world.com | bio-world.com | 82% | – | #901,632 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for ExonBio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as ExonBio (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Exonbio
Complete news archive for ExonBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ExonBio
ExonBio was founded in 1996 and raised its 1st funding round 14 years after it was founded.
ExonBio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
ExonBio provides services in recombinant antibody development (rabbit, chicken, and Llama), antibody engineering, protein production using mammalian expression ( transient expression, mammalian expression systems, and stable cell pool) and bacterial expression system, molecular biology services (gene synthesis, gene cloning, site-directed mutagenesis). Additionally, the company manufactures some reagents for research such as enzymes, competent cells, and growth factors.
ExonBio's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
ExonBio offers SARS-CoV-2 Antibody, Influenza A Antibody, Influenza B Antibody, Ebola Antibody, and SPIN Platform.
ExonBio has 1 investor. Key investors include HHS.